Romiplostim News
Romiplostim currently has 0 news articles, with 20 predicted indications.
This page combines the AI-predicted indications for Romiplostim with the latest health news. Indications highlighted in orange have recent news coverage.
Drug Information
- Original indication: Adults: Nplate is indicated for the treatment of primary immune thrombocytopenia (ITP) in adult patients who are refractory to other treatments (e.g. corticosteroids, immunoglobulins). Paediatrics:...
- Evidence level: L5
- Predicted indications (20):
- primary release disorder of platelets (100.0%)
- pseudo-von Willebrand disease (100.0%)
- Glanzmann thrombasthenia (100.0%)
- fetal and neonatal alloimmune thrombocytopenia (100.0%)
- Scott syndrome (100.0%)
- hemorrhagic disorder due to a constitutional thrombocytopenia (100.0%)
- bleeding diathesis due to a collagen receptor defect (100.0%)
- platelet-type bleeding disorder (99.9%)
- autosomal dominant macrothrombocytopenia (99.9%)
- Ehlers-Danlos syndrome, fibronectinemic type (99.8%)
- paroxysmal nocturnal hemoglobinuria (99.6%)
- proteinuria (99.6%)
- neurolymphomatosis (99.6%)
- mixed-type autoimmune hemolytic anemia (99.6%)
- drug-induced autoimmune hemolytic anemia (99.5%)
- neonatal autoimmune hemolytic anemia (99.5%)
- plasmacytoma (99.5%)
- primary CD59 deficiency (99.4%)
- Peyronie disease (99.3%)
- cold agglutinin disease (99.3%)
Related News (0)
No related news yet. When news mentions this drug, it will be collected and shown here automatically.
Disclaimer: The news on this page is collected automatically and is for research reference only; it does not constitute medical advice.